Lab In The News
Wistar Receives More than $12 Million to Fund Innovative Clinical Research on the Impact of Opioid Use on Response to Therapy in People Living with HIV
PHILADELPHIA — (September 24, 2019) — The Wistar Institute was awarded two major grants totaling more than $12 million from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to fund an international multidisciplinary clinical research consort
Spotlight on Wistar COVID-19 Researchers: Luis Montaner, D.V.M., D.Phil., & Joseph Salvino, Ph.D.
Dr. Luis Montaner is an HIV expert focused on finding new ways to boost the natural function of the immune system to combat infection or viral-associated disease. Dr.
The Storm Brewing Inside: Immune Systems Go Wild During SARS-CoV-2 Infection
Despite an unprecedented volume of research, there are still many unanswered questions on COVID-19, especially regarding the extremely varied clinical course the disease takes, ranging from asymptomatic to severe, even fatal.
The Montaner Laboratory
At Wistar, the Montaner laboratory focuses on immune system-based research using laboratory models of virus infection, animal models of infection and or cancer, and clinical cohort studies to provide a clinic-to-bench research program that informs new strategies to combat HIV and or cancer. The Montaner lab is also a leading center for a Martin Delaney Collaboratory focused on HIV cure-directed research (see beat-hiv.org). Patient and animal-based collaborative studies —and thus, their impact—extend from Philadelphia to multiple US states for coast-to-coast, Puerto Rico, Mexico, South America, and Southern Africa, and focus on:
- identifying new strategies to reverse mechanisms of immunodeficiency caused by viral infection and/or cancer processes via testing new immune enhancing products.
- exploring new ways to augment HIV-1 control beyond current therapies in order to achieve durable remission and or permanent control of infection without the need for continued antiretroviral therapy.
- understanding the natural ability of our immune system to respond to viruses and comparing that to the immune response of a rare subset of people who are exposed to—yet uninfected by—HIV-1 or are infected yet retain an inherent ability to control their HIV-1 infection.
Watch this video to learn more about HIV cure research.
Research Assistant Professor
Ian Tietjen, Ph.D.
Senior Staff Scientists
Livio Azzoni, M.D., Ph.D.
Emmanouil Papasavvas, Ph.D.
Costin Tomescu, Ph.D.
Zhe Yuan, Ph.D.
Jocelyn Rivera Ortiz, Ph.D.
Xue Yang, Ph.D.
Krystal Colon-Rivera, Ph.D.
Ken Lynn, R.N.
BSL-3 Laboratory Manager
The Montaner lab pursues a variety of projects at any given time related to the understanding and eventual cure of the HIV-1 virus.
View a list of current projects being pursued by the Montaner lab and its many collaborators.
Abdel-Mohsen, M., Kuri-Cervantes, L., Grau-Exposito, J., Spivak, A.M., Nell, R.A., Tomescu, C., Vadrevu, S.K., Giron, L.B., Serra-Peinado, C., Genescà, M., et al. "CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells." Sci Transl Med. 2018 Apr 18;10(437). pii: eaar6759. doi: 10.1126/scitranslmed.aar6759.
Abdulhaqq, S.A., Martinez, M., Kang, G., Rodriguez, I.V., Nichols, S.M., Beaumont, D., Joseph, J., Azzoni, L., Yin, X., Wise, M., et al. “Repeated semen exposure decreases cervicovaginal SIVmac251 infection in rhesus macaques.” Nat Commun. 2019 Aug 21;10(1):3753. doi: 10.1038/s41467-019-11814-5.
Papasavvas, E., Kossenkov, A.V., Azzoni, L., Zetola, N.M., Mackiewicz, A., Ross, B.N., Fair, M., Vadrevu, S., Ramogola-Masire, D., Sanne, I., et al. “Gene expression profiling informs HPV cervical histopathology but not recurrence/relapse after LEEP in ART-suppressed HIV+HPV+ women.” Carcinogenesis. 2019 Apr 29;40(2):225-233. doi: 10.1093/carcin/bgy149.
Cai, Y., Abdel-Mohsen, M., Tomescu, C., Xue, F., Wu, G., Howell, B.J., Ai, Y., Sun, J., Azzoni, L., Le Coz, C., et al. “BCL6 Inhibitor-Mediated Downregulation of Phosphorylated SAMHD1 and T Cell Activation Are Associated with Decreased HIV Infection and Reactivation.” J Virol. 2019 Jan 4;93(2). pii: e01073-18. doi: 10.1128/JVI.01073-18. Print 2019 Jan 15.
Tomescu, C., Mavilio, D., Montaner, L.J. "Lysis of HIV-1-infected autologous CD4+ primary T cells by interferon-alpha-activated NK cells requires NKp46 and NKG2D." AIDS. 2015 Sep 10;29(14):1767-73. doi: 10.1097/QAD.0000000000000777.
Qin Liu, M.D., Ph.D.
Professor, Molecular & Cellular Oncogenesis Program, The Wistar Institute Cancer Center